Yosuke Aoki

发表

Physicochemical and pharmacokinetic characterization of amorphous solid dispersion of tranilast with enhanced solubility in gastric fluid and improved oral bioavailability.

S. Onoue, S. Yamada, Yoshiki Kojo, 2012, Drug metabolism and pharmacokinetics.

Self-assembled micellar formulation of chafuroside A with improved anti-inflammatory effects in experimental asthma/COPD-model rats.

S. Onoue, S. Yamada, Yosuke Aoki, 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Inhalable powder formulation of a stabilized vasoactive intestinal peptide (VIP) derivative: Anti-inflammatory effect in experimental asthmatic rats

S. Misaka, S. Onoue, S. Yamada, 2010, Peptides.

Effect of water-extract Mekabu powder on defecation and fecal bacterial flora of elderly people in nursing homes

A. Ikemi, Yosuke Aoki, K. Katai, 2018 .

Respirable dry powder formulation of bleomycin for developing a pulmonary fibrosis animal model.

S. Onoue, S. Yamada, Yoshiki Kojo, 2012, Journal of pharmaceutical sciences.

Development of inhalable nanocrystalline solid dispersion of tranilast for airway inflammatory diseases.

S. Onoue, S. Yamada, Hideyuki Sato, 2011, Journal of pharmaceutical sciences.

Inhalable powder formulation of vasoactive intestinal peptide derivative, [R15,20,21, L17]-VIP-GRR, attenuated neutrophilic airway inflammation in cigarette smoke-exposed rats.

S. Misaka, S. Onoue, S. Yamada, 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Formulation design and in vivo evaluation of dry powder inhalation system of new vasoactive intestinal peptide derivative ([R(15, 20, 21), L(17), A(24,25), des-N(28)]-VIP-GRR) in experimental asthma/COPD model rats.

S. Misaka, S. Onoue, S. Yamada, 2011, International journal of pharmaceutics.

Inhalable dry-emulsion formulation of cyclosporine A with improved anti-inflammatory effects in experimental asthma/COPD-model rats.

S. Onoue, S. Yamada, Koichi Wada, 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Inhalable Powder Formulation of Pirfenidone with Reduced Phototoxic Risk for Treatment of Pulmonary Fibrosis

S. Onoue, S. Yamada, Yoshiki Kojo, 2013, Pharmaceutical Research.

Inhalable powder formulation of vasoactive intestinal peptide derivatives, [R^ , L^ ]-VIP-GRR, attenuated neutrophilic airway inflammation in cigarette smoke-exposed rats

S. Misaka, S. Onoue, S. Yamada, 2011 .

Novel vasoactive intestinal peptide derivatives with improved stability protect rat alveolar L2 cells from cigarette smoke-induced cytotoxicity and apoptosis

S. Misaka, S. Onoue, S. Yamada, 2011, Peptides.

Stable dry powder inhaler formulation of tranilast attenuated antigen-evoked airway inflammation in rats.

S. Onoue, S. Yamada, Hideyuki Sato, 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Inhalable Powder Formulation of Pirfenidone with Reduced Phototoxic Risk for Treatment of Pulmonary Fibrosis

S. Onoue, S. Yamada, Yoshiki Kojo, 2013, Pharmaceutical Research.

Novel vasoactive intestinal peptide derivatives with improved stability protect rat alveolar L2 cells from cigarette smoke-induced cytotoxicity and apoptosis

S. Misaka, S. Onoue, S. Yamada, 2011, Peptides.